Výsledky vyhledávání - "Amy L Schroeder"

Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019

Autor: Allison A. Petrilla, Alison R. Silverstein, Anthony Eccleston, Allison Thompson, Julia Brinkmann, Temitope Bello, Jane Chang, Joseph C Cappelleri, Sanjana Chandrasekar, Amy L Schroeder

Publikováno v: Journal of Clinical Oncology. 41:473-473

473 Background: For patients with intermediate- to high-risk non-muscle invasive bladder cancer (NMIBC), standard of care includes transurethral resection (TURBT) followed by induction and maintenance intravesical immunotherapy with Bacillus Calmette

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a74afb18226fff570e747c33491a88f
https://doi.org/10.1200/jco.2023.41.6_suppl.473

Zobrazit plný text záznamu

Characteristics of Medicare patients with relapsed/refractory acute lymphoblastic leukemia initiating treatment with inotuzumab ozogamicin, blinatumomab, or other agents

Autor: T. Alexander Russell-Smith, Richa Shah, Alison R. Silverstein, Allison A. Petrilla, Brian Leinwand, Diane Norris, Amy L Schroeder

Publikováno v: Journal of Clinical Oncology. 40:e19009-e19009

e19009 Background: B-cell precursor acute lymphoblastic leukemia (ALL) represents the majority of ALL cases. The INO-VATE and TOWER trials demonstrated that adult patients with relapsed/refractory (RR) B-cell precursor ALL treated with inotuzumab ozo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::416ba18aed5e9b180f4543ff4026132c
https://doi.org/10.1200/jco.2022.40.16_suppl.e19009

Zobrazit plný text záznamu

Concordance of provider treatment patterns with NCCN oncology treatment guidelines (NCCN Guidelines) for metastatic non-small cell lung cancer (mNSCLC)

Autor: Meghan J. Mooradian, Biruk Bekele, Brian Seal, Allison Petrilla, Dana Macher, Candice Yong, Amy L Schroeder

Publikováno v: Journal of Clinical Oncology. 38:e21574-e21574

e21574 Background: mNSCLC clinical treatment guidelines are rapidly evolving, however, their influence on prescriber use of anti-cancer treatment regimens is not known. This retrospective study evaluated whether US patients with mNSCLC received first

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1414d476f89a3f407495d4df2b9be225
https://doi.org/10.1200/jco.2020.38.15_suppl.e21574

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání